SAN DIEGO, March 11, 2025 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX ) will participate at the Stifel 2025 Virtual CNS Forum at 1:30 p.m. Eastern Time on Tuesday, March 18, 2025. Chief ...

Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today announced that on March 10, 2025, the Compensation Committee of the ...

On Dec 12, 2024, the US Food and Drug Administration (FDA) approved crinecerfont for adults and paediatric patients with ...

Neurocrine Biosciences has commenced the Phase I clinical trial of its oral, small molecule vesicular monoamine transporter 2 ...

Boys and young adult male patients with congenital adrenal hyperplasia receiving glucocorticoid treatment have lower bone ...

Commercial Preparations On-Track Ahead of September 25, 2025 PDUFA Date Including Regulatory Review Process, Organizational Build, and Key ...

HBM Alpha Therapeutics Inc. signed a potential $395 million licensing deal Feb. 26 with an unnamed “business partner” for its endocrine asset, HAT-001, adding another contender to the congenital ...

The therapy—called HAT001 at HBMAT and HBM9013 at Harbour—is an anti-CRH-neutralizing antibody that is being considered for a range of disorders including congenital adrenal hyperplasia (CAH).

Inc., an innovative biotechnology company incubated by Harbour BioMed (HKEX: 02142), announced a strategic collaboration and license agreement with a business partner to advance novel therapies ...

There are 2 adrenal glands, one above each kidney. They make hormones that help the body work properly and are vital to life. Most tumours of the adrenal gland are called adenomas. These are not ...